Get the Stockscreener App
8.38
2.78%
-0.24
Entrada Therapeutics Inc stock is traded at $8.38, with a volume of 110.35K.
It is down -2.78% in the last 24 hours and up +1.33% over the past month.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
See More
Previous Close:
$8.62
Open:
$8.67
24h Volume:
110.35K
Relative Volume:
0.84
Market Cap:
$350.31M
Revenue:
$239.40M
Net Income/Loss:
$104.44M
P/E Ratio:
2.8311
EPS:
2.96
Net Cash Flow:
$-18.50M
1W Performance:
-9.21%
1M Performance:
+1.33%
6M Performance:
-57.72%
1Y Performance:
-41.64%
1-Day Range:
$8.34
$9.15
1-Week Range:
$7.71
$9.27
52-Week Range:
$7.10
$21.79
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Name
Entrada Therapeutics Inc
Sector
Industry
Phone
857-305-1825
Address
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
8.38 | 350.31M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Jan-05-24 | Initiated | Oppenheimer | Outperform |
| Apr-03-23 | Initiated | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Stock (TRDA) Latest News
Entrada Therapeutics: Strategic Advancements in DMD Pipeline Drive Buy Rating - TipRanks
Entrada Therapeutics reports Q1 EPS (42c), consensus (77c) - TipRanks
Entrada Therapeutics earnings beat by $0.31, revenue fell short of estimates - Investing.com
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Entrada Therapeutics Reports First Quarter 2025 Financial Results - The Manila Times
First Trust Advisors LP Sells 7,800 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
MetLife Investment Management LLC Acquires 1,731 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Wells Fargo & Company MN Buys 3,357 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Barclays PLC Has $887,000 Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Form 8-KCurrent report - ADVFN
Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives - insights.citeline.com
Layoff Tracker: Pliant Cuts 45% of Staff To Extend Cash Runway - BioSpace
Invesco Ltd. Takes Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics (TRDA) Projected to Post Earnings on Tuesday - Defense World
Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for - MSN
Arvinas, Entrada cut staff; Merck builds US hub for Keytruda - BioPharma Dive
Legal & General Group Plc Has $344,000 Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Immunic’s stock falls on multiple sclerosis data; Entrada’s layoffs - Endpoints News
JPMorgan Chase & Co. Raises Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics IncApproves Strategic Plan Focusing On DMD ProgramsSEC Filing - marketscreener.com
Russell Investments Group Ltd. Raises Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Geode Capital Management LLC Decreases Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
LPL Financial LLC Raises Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Trend Tracker for (TRDA) - news.stocktradersdaily.com
Vanguard Group Inc. Has $25.32 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
CandE Benchmark Research Case Study – Entrada Therapeutics - ere.net
KLP Kapitalforvaltning AS Invests $36,000 in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
American Century Companies Inc. Purchases 8,985 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock? - Yahoo Finance
HC Wainwright Issues Negative Forecast for TRDA Earnings - MarketBeat
Lacklustre Performance Is Driving Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) 27% Price Drop - simplywall.st
HC Wainwright Issues Pessimistic Forecast for TRDA Earnings - Defense World
(TRDA) On The My Stocks Page - news.stocktradersdaily.com
Entrada Therapeutics (NASDAQ:TRDA) Receives Buy Rating from HC Wainwright - Defense World
Entrada Therapeutics Gains Momentum Amid Exon-Skipping Advances and Regulatory Approvals - TipRanks
Entrada Therapeutics stock rating holds with $20 target By Investing.com - Investing.com UK
Entrada Therapeutics stock hits 52-week low at $9.74 By Investing.com - Investing.com UK
Charles Schwab Investment Management Inc. Boosts Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Roth/MKM maintains Buy on Entrada stock, $23 target By Investing.com - Investing.com Canada
Positive Outlook on Entrada Therapeutics Inc Due to Promising Developments in Duchenne Muscular Dystrophy Treatment - TipRanks
Entrada Therapeutics gets approval to start trial of its DMD treatment in the UK (TRDA:NASDAQ) - Seeking Alpha
Entrada Therapeutics rises on UK approval for muscle-wasting drug study - TradingView
Entrada’s ENTR-601-45 gains clearance in UK to enter clinic for Duchenne muscular dystrophy - BioWorld MedTech
Entrada Therapeutics begins Duchenne study in UK By Investing.com - Investing.com Australia
Entrada Therapeutics begins Duchenne study in UK - Investing.com India
Entrada Therapeutics Gains UK Approval for DMD Study - TipRanks
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping - The Manila Times
Major Breakthrough: Entrada's DMD Drug Gets Green Light for UK Clinical Trials - Stock Titan
Bank of New York Mellon Corp Lowers Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics stock hits 52-week low at $10.21 - Investing.com
Entrada Therapeutics stock hits 52-week low at $10.21 By Investing.com - Investing.com UK
Entrada Therapeutics Inc Stock (TRDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):